Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | RAF1 | P04049 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369908 | 0.90 | KDR (0.56) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4367856 | 0.85 | KDR (0.55) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4370234 | 0.84 | KDR (0.55) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4372559 | 0.84 | KDR (0.85) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL13862513 | 0.84 | KDR (0.61) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4161669 | 0.84 | KDR (0.56) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4375547 | 0.82 | KDR (0.53) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL2892694 | 0.82 | RAF1 (0.69) | KDRRAF1BRAF | |
| SCHEMBL13861947 | 0.81 | KDR (0.61) | KDRRAF1BRAFPDE10ACSNK1A1 | |
| SCHEMBL4369261 | 0.80 | CSNK1A1 (0.54) | KDRRAF1BRAFPDE10ACSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885RAF1 1846/4885BRAF 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.